{"id":"NCT01475851","sponsor":"GlaxoSmithKline","briefTitle":"Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs","officialTitle":"A Multi-center, Open-label Study of GSK548470 (Tenofovir Disoproxil Fumarate) in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-06","completion":"2014-10","firstPosted":"2011-11-21","resultsPosted":"2013-11-04","lastUpdate":"2015-06-22"},"enrollment":34,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis B, Chronic"],"interventions":[{"type":"DRUG","name":"GSK548470 300 mg tablet","otherNames":["GSK548470"]}],"arms":[{"label":"GSK548470 300 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in Japanese patients with compensated chronic hepatitis B with poor response to other drugs.","primaryOutcome":{"measure":"Number of Participants With HBV DNA Level < 2.1 log10 Copies/mL at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"LAM 100 mg/TDF 300 mg","deltaMin":8,"sd":null},{"arm":"ETV 0.5 mg/TDF 300 mg","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":18},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":["27862721"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":13},"commonTop":["Nasopharyngitis","Rash","Headache","Alanine aminotransferase increased","Hepatic steatosis"]}}